EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Safety of SGLT2 inhibitors in chronic kidney disease patients during Ramadan fasting: a prospective cohort study

Ahmed Elkeraie, Mohammed Elraggal, Merna AbouKhatwa, Mariam E Omar, Rowan Zyada

Journal of Nephrology · 2025

DOI: 10.1007/s40620-025-02438-8 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Nephrology, 2025. Verfasst von Ahmed Elkeraie und 4 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. drahmed@hotmail.com. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Sodium-Glucose Transporter 2 Inhibitors, Fasting, Islam. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The safety of sodium-glucose co-transporter 2 inhibitors (SGLT2i) during fasting in patients with chronic kidney disease (CKD) remains underexplored. This study investigates the risk of acute kidney injury (AKI) in patients with CKD who are fasting and taking SGLT2i, and also examines the long-term estimated glomerular filtration rate (eGFR) outcomes over 6 months after fasting.

Methods

In this prospective cohort study conducted at the Kidney and Urology Centre, Alexandria, Egypt, 236 Muslim patients with CKD were enrolled during Ramadan. Patients were stratified into two groups: SGLT2i users (n = 56) and non-users (n = 180). Weekly serum creatinine and eGFR were monitored during Ramadan, with monthly follow-up for 6 months post-fasting. AKI was defined as an increase in serum creatinine ≥ 0.3 mg/dL. Logistic regression was used to identify AKI predictors.

Results

The incidence of AKI was 17.8% among SGLT2i users and 23.3% among non-users (RR 0.76; 95% CI 0.41–1.42; p = 0.38), indicating no significant difference. No significant changes were observed in eGFR between the two groups at the end of Ramadan or during the 6-month follow-up. AKI incidence significantly increased with CKD severity (p = 0.036), with 37.5% of CKD stage 5 patients experiencing at least one episode. Logistic regression identified older age and lower baseline eGFR as significant predictors of developing AKI; SGLT2i use was not independently associated with the risk of developing an AKI episode.

Conclusion

SGLT2i use in CKD patients during Ramadan fasting does not increase the risk of AKI. These findings may offer valuable guidance for clinicians managing fasting patients with CKD on SGLT2i therapy. Graphical abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsFastingIslamAcute Kidney InjuryHumansMaleFemaleProspective StudiesMiddle AgedGlomerular Filtration RateAdultIncidenceRisk FactorsAgedEgyptCreatinineTime Factors

Stichwörter der Autor:innen

Chronic kidney diseaseFastingSGLT2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsCreatinine

Autor:innen und Institutionen

  • Nephrology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt. drahmed@hotmail.com.
  • Nephrology Department, Kidney and Urology Center, Alexandria, Egypt. drahmed@hotmail.com.
  • Nephrology Department, Kidney and Urology Center, Alexandria, Egypt.
  • Nephrology Department, Johns Hopkins Aramco Healthcare, Dhahran, Saudi Arabia.
  • Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt.
  • Nephrology Department, EL-Qabbary Hospital, Alexandria, Egypt.

Zitieren

APA

Elkeraie, A., Elraggal, M., AbouKhatwa, M., Omar, M. E., & Zyada, R. (2025). Safety of SGLT2 inhibitors in chronic kidney disease patients during Ramadan fasting: a prospective cohort study. Journal of Nephrology. https://doi.org/10.1007/s40620-025-02438-8

Vancouver

Elkeraie A, Elraggal M, AbouKhatwa M, Omar ME, Zyada R. Safety of SGLT2 inhibitors in chronic kidney disease patients during Ramadan fasting: a prospective cohort study. Journal of Nephrology. 2025. doi:10.1007/s40620-025-02438-8

BibTeX
@article{Elkeraie2025,
  author = {Elkeraie, Ahmed and Elraggal, Mohammed and AbouKhatwa, Merna and Omar, Mariam E and Zyada, Rowan},
  title = {Safety of SGLT2 inhibitors in chronic kidney disease patients during Ramadan fasting: a prospective cohort study},
  journal = {Journal of Nephrology},
  year = {2025},
  doi = {10.1007/s40620-025-02438-8}
}
Kostenlos starten →